Pricing Log in Create free account

Galectin Therapeutics Inc. (GALT) vs Scribe Therapeutics Inc. (SCTX)

Galectin Therapeutics Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Galectin Therapeutics Inc. and Scribe Therapeutics Inc. are of similar size ($301.0M and $293.1M). Across the 4 metrics below, Galectin Therapeutics Inc. leads on 2 and Scribe Therapeutics Inc. on 2.

Valuation

Metric GALT SCTX Biotechnology median
P/E n/m — 10.60
P/S n/m n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (13.69%) — (32.88%)
Free cash flow yield (7.68%) 0.00% (23.13%)

Profitability

Metric GALT SCTX Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity 21.69% — (51.96%)
Return on assets (184.22%) — (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GALT SCTX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 36.84% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GALT SCTX Biotechnology median
Debt to equity (0.76) 0.00 0.00
Current ratio 0.10 0.57 4.97
Net debt to EBITDA (5.79) 0.00 1.01

Dividend

Metric GALT SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GALT SCTX Biotechnology median
Market cap 301.04m 293.06m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack